Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the update.
outstanding shares of Common Stock as of April 30, 2020 in this Current Report on Form 8-K. The number of shares of Common Stock of the Company outstanding on April 30, 2020 was 109,553,548. The number of authorized shares of Common Stock of the Company remains at 190,000,000.
The next couple of weeks.
it's coming
In addition to their cutting-edge therapies, Inspyr's board of directors have extensive experience along with strong ties to Pfizer (PFE), Glaxo Smith Kline (GSK), Exelixis (EXEL), and Astellas Pharma (ALPMF). In previous years, Inspyr Therapeutics (formerly GenSpera) has raised tens of millions in equity funding, received millions in grants, and on 1/21/20, leading hedge fund Shabby Management LLC and their associated funds announced an ownership stake of nearly 40% in NSPX.
Then on 3/6/20, Inspyr filed an 8-K with the SEC in that the company sold an aggregate of $250,000 of senior convertible debentures (“Debentures”) for cash to existing accredited institutional investors of the Company (the “Offering”) with an original set conversion price was $0.33.
Inspyr Therapeutics (NSPX)
Inspyr Therapeutics is an integrated clinical-stage biopharmaceutical company that is focused on developing targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer along with the development of novel therapies to treat cancer, inflammation, and other serious diseases.
Inspyr, like Gilead’s Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment. Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. Their pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist.
While developing new A2A and A2B adenosine antagonists as well as dual A2A/A2B adenosine antagonist with improved drug like properties resulting in better bioavailability for the treatment of:
? Cancer ? Asthma ? Diabetes
Broad pipeline of novel therapies for oncology and inflammation.
Lewis and Clark's pipeline of novel proprietary therapies includes four lead programs: a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. These therapies are highly potent and selective, with important molecular properties that enable enhanced distribution in tissue and penetration of human skin. These therapies are in advanced preclinical development.
The dual A2A/A2B antagonist has both immune function modulation and anti-angiogenic properties and thus has potential as an immuno-oncology and anti-angiogenic agent to treat multiple types of solid and hematological malignancies.
The A2A agonists offers the potential to treat inflammatory and autoimmune diseases as arthritis, Crohn's disease, diabetic nephropathy, and psoriasis.
The A2B antagonist offers the potential to treat asthma, type 2 diabetes, atherosclerosis, and nonalcoholic fatty liver disease.
Inspyr's lead therapy, Mipsagargin, currently is in development for the treatment of solid tumors.
For liver cancer, Mipsagargin in combination with Nexavar(R) is being evaluated in a preclinical study in liver tumor models that express different levels of PSMA, the target of Mipsagargin. Inspyr is finalizing the design of a clinical study to examine the potential benefits of Mipsagargin in combination with Nexavar(R) in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
For gastric cancer, Inspyr has initiated a preclinical study in gastric cancer tumor models that express different levels of PSMA. In this initial study, Mipsagargin will be evaluated first in combination with paclitaxel and in a subsequent study will be evaluated in combination with DC101 (Cyramza(R) surrogate antibody).
Utilizing Lewis and Clark's wet laboratory facilities, Inspyr has the potential to internally develop additional pro-drugs targeting PSMA with different toxic payloads.
A potential cancer killer not in the commercial markets yet.
In addition to their cutting-edge therapies, Inspyr's board of directors have extensive experience along with strong ties to Pfizer (PFE), Glaxo Smith Kline (GSK), Exelixis (EXEL), and Astellas Pharma (ALPMF). In previous years, Inspyr Therapeutics (formerly GenSpera) has raised tens of millions in equity funding, received millions in grants, and on 1/21/20, leading hedge fund Shabby Management LLC and their associated funds announced an ownership stake of nearly 40% in NSPX.
Then on 3/6/20, Inspyr filed an 8-K with the SEC in that the company sold an aggregate of $250,000 of senior convertible debentures (“Debentures”) for cash to existing accredited institutional investors of the Company (the “Offering”) with an original set conversion price was $0.33.
Looking at the recent surge in volume and the share price of NSPX over the past few days, it's reason to think there is some serious correlation connecting the funds behind Inspyr, recent disclosures, their extensive patent portfolio, and the proprietary technology and drugs they have that can be quickly repurposed to treat and possibly cure this new novel coronavirus COVID-19 and put an end to this global pandemic.
From annual report.Business of the Company
The Company is currently exploring opportunities to acquire attractive operating businesses or other assets in the Asia
Pacific region. The Company is an Exploration Stage Company, as defined by Financial Accounting Standards Board
(“FASB”) Accounting Standards Codification (“ASC”) 915, Development Stage Entities.
Thank you
TJG.how is DC Group related to Smart Crown International? Thank you for your reply.
ok how is DC Group related to Smart Crown International? Thank you for your reply.
TJG .Smart Crown Ltd received the control block ? wtf
UNEQ is reverse merging with Synergy Medical Supplies.
Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certificate to Accompany Restated Articles or Amended and Restated Articles (PURSUANT TO NRS 78.403) Officer's Statement (PURSUANT TO NRS 80.030) 4. Effective date and Time: (Optional) Date: 02/21/2020Time: (must not be later than 90 days after the certificate is filed) 5. Information Being Changed: (Domestic corporations only) Changes to takes the following effect:The entity name has been amended.The registered agent has been changed. (attach Certificate of Acceptance from new registered agent)The purpose of the entity has been amended.The authorized shares have been amended.The directors, managers or general partners have been amended.IRS tax language has been added.Articles have been added.Articles have been deletedOther. The articles have been amended as follows: (provide article numbers, if available) (attach additional page(s) if necessary)6. Signature: (Required) XSignature of Officer, Incorporator or Authorized SignerAbel Haque Title Officer *If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to lim
Pink No Information
Dark or Defunct
Transfer Agent Verified
Shell
stop
Thank you.
You are sick Smilin.
.008
QUTR 0,008 COMING
QUTR 0,008 COMING
$QUTR...12/23/2019, Custodianship GRANTED.
QUTR next big Lazar play.
Bitcoin Bitcoin (BTC)
$8,626.70 597.05 (7.44%)
435.74 (5.44%)
The Company and Digihost are in the process of preparing required disclosure with respect to the Proposed Transaction, and otherwise working toward meeting the requirements of the TSXV with respect to the Proposed Transaction.
The HashChain Shares currently remain halted from trading and are not expected to resume trading until an information circular in respect of the Proposed Transaction has been prepared and filed on SEDAR, and the requirements of the TSXV with respect to the Proposed Transaction have otherwise been fulfilled.
The Proposed Transaction cannot close until the required shareholder approvals are obtained and there can be no assurance that the Proposed Transaction will be completed as proposed or at all.
05/20/2019 Status Check (9:00 AM) (Judicial Officer Hardy, Joe)
UCPA Penny Stock Exempt
This security is exempt from the definition of a Penny Stock under SEC under Rule 240.3a51-1 because it meets one of the following tests: 1) A price of over $5 per share, 2) the issuer has Average Revenue of at least $6 million for the last 3 years, or 3) the issuer has Net Tangible Assets in excess of $2 million if the issuer has been in continuous operations for at least 3 years or $5 million if less than 3 years.
Why is this no more Penny Stock Exempt..??Not sure, maybe the uplisting?
UCPA no more Penny Stock Exempt..??
Powerbattles great DD. The way this trades confirms..clean stock .
This is real gold ticker. ahoj from Czech Republic.
4 Mar
Guess who's a judge at the Festival of Media Global Awards in Rome? Tre Kronor's MD, Henrik Von Bahr. Good Luck Henrik!
After almost 12 years in the industry, we are incredibly happy to tell you that it is time for us to expand, this time only to Gothenburg! We have previously had customers based in Gothenburg and other customer projects at the time, therefore this felt very natural. In mid-March, we will open the doors for the new office with Max Hallenberg as head of the agency. Together with Max, we will initially start recruiting the right staff who share our values ??around creating long-term customer value.
“The competition in Gothenburg is tough, both from network agencies and private agencies. But I think we have the opportunity to come up with more qualitative advice and hopefully be more capable of building good and good customer relationships. ”Says Max Hallenberg to Dagens Media.
At Tre Kronor, we see great opportunities with the market in Gothenburg and are so keen on getting started.
As we grow, our customer list also makes it
A rewarding start to the new year with a new office in Gothenburg and now also two new customers, Kronfågel and Enjoy Wine, welcome!
We are incredibly happy and proud that both Kronfågel and Enjoy Wine have chosen us as their new media agency. We look forward to working with two such strong brands and companies that share many of our own values ??regarding sustainability and the importance of power-driven communication.
In 2019, we will gradually develop Kronfågel's brand and communication, the core will be relevant to its customers and consumers, and inspire good choices - taste as well.
Enjoy Wine & Spirits are among the largest wine importers in the Swedish market. There, too, we will work on developing communication for their own brands such as Tr3 Apes and Barrels & Drums.
“My experience with the team at Tre Kronor Media is that they are business oriented and service minded. We find that the company shares the values ??we have at Enjoy Wine & Spirits. As passionate as we are to create and trade drinks that contribute to a sustainable drinking culture, we feel that they are for their business. We are both entrepreneur-driven companies that like innovation, ”says Maria Wästlund, Marketing Manager at Enjoy Wine & Spirits, in a press release.